---
document_datetime: 2025-12-02 05:26:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/unituxin.html
document_name: unituxin.html
version: success
processing_time: 0.1030475
conversion_datetime: 2025-12-27 18:02:31.023623
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Unituxin

[RSS](/en/individual-human-medicine.xml/67018)

##### Withdrawn

This medicine's authorisation has been withdrawn

dinutuximab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Unituxin](#news-on)
- [More information on Unituxin](#more-information-on-unituxin-852)
- [More information on Unituxin](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 20 March 2017, the European Commission withdrew the marketing authorisation for Unituxin (dinutuximab) in the European Union (EU). The withdrawal was initiated by the marketing authorisation holder (MAH), United Therapeutics Europe Ltd, which had requested the European Commission to withdraw the marketing authorisation due to short- and intermediate- term inability to supply Unituxin in sufficient quantities for meeting current global demands.

The MAH has confirmed that it has no future plans to commercialise Unituxin in the EU until the supply issues have been resolved. Unituxin was granted marketing authorisation in the EU on 14 August 2015 for the treatment of highrisk neuroblastoma. The marketing authorisation was initially valid for a 5-year period. The MAH has confirmed that any neuroblastoma patients who are currently receiving Unituxin treatment will have the possibility to receive the full treatment until completion of the 5 courses. No new patients with high risk neuroblastoma will be started on Unituxin therapy due to the lack of drug supply.

The European Public Assessment Report (EPAR) for Unituxin is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Unituxin : EPAR - Summary for the public

Reference Number: EMA/364550/2015

English (EN) (517.15 KB - PDF)

**First published:** 01/09/2015

**Last updated:** 28/04/2017

[View](/en/documents/overview/unituxin-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-329)

български (BG) (598.27 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/bg/documents/overview/unituxin-epar-summary-public_bg.pdf)

español (ES) (516.57 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/es/documents/overview/unituxin-epar-summary-public_es.pdf)

čeština (CS) (579.85 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/cs/documents/overview/unituxin-epar-summary-public_cs.pdf)

dansk (DA) (515.78 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/da/documents/overview/unituxin-epar-summary-public_da.pdf)

Deutsch (DE) (1021.5 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/de/documents/overview/unituxin-epar-summary-public_de.pdf)

eesti keel (ET) (514.83 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/et/documents/overview/unituxin-epar-summary-public_et.pdf)

ελληνικά (EL) (602.42 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/el/documents/overview/unituxin-epar-summary-public_el.pdf)

français (FR) (517.31 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/fr/documents/overview/unituxin-epar-summary-public_fr.pdf)

hrvatski (HR) (537.25 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/hr/documents/overview/unituxin-epar-summary-public_hr.pdf)

italiano (IT) (515.34 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/it/documents/overview/unituxin-epar-summary-public_it.pdf)

latviešu valoda (LV) (578.21 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/lv/documents/overview/unituxin-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (541.19 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/lt/documents/overview/unituxin-epar-summary-public_lt.pdf)

magyar (HU) (573.41 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/hu/documents/overview/unituxin-epar-summary-public_hu.pdf)

Malti (MT) (579.9 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/mt/documents/overview/unituxin-epar-summary-public_mt.pdf)

Nederlands (NL) (516.48 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/nl/documents/overview/unituxin-epar-summary-public_nl.pdf)

polski (PL) (580.23 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/pl/documents/overview/unituxin-epar-summary-public_pl.pdf)

português (PT) (516.6 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/pt/documents/overview/unituxin-epar-summary-public_pt.pdf)

română (RO) (539.94 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/ro/documents/overview/unituxin-epar-summary-public_ro.pdf)

slovenčina (SK) (1.03 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sk/documents/overview/unituxin-epar-summary-public_sk.pdf)

slovenščina (SL) (97.58 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sl/documents/overview/unituxin-epar-summary-public_sl.pdf)

Suomi (FI) (515.31 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/fi/documents/overview/unituxin-epar-summary-public_fi.pdf)

svenska (SV) (515.89 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sv/documents/overview/unituxin-epar-summary-public_sv.pdf)

Unituxin : EPAR - Risk-management-plan summary

English (EN) (513.43 KB - PDF)

**First published:** 01/09/2015

**Last updated:** 28/04/2017

[View](/en/documents/rmp-summary/unituxin-epar-risk-management-plan-summary_en.pdf)

## Product information

Unituxin : EPAR - Product Information

English (EN) (746.76 KB - PDF)

**First published:** 01/09/2015

**Last updated:** 28/04/2017

[View](/en/documents/product-information/unituxin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-584)

български (BG) (1.62 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/bg/documents/product-information/unituxin-epar-product-information_bg.pdf)

español (ES) (766.26 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/es/documents/product-information/unituxin-epar-product-information_es.pdf)

čeština (CS) (1.24 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/cs/documents/product-information/unituxin-epar-product-information_cs.pdf)

dansk (DA) (755.71 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/da/documents/product-information/unituxin-epar-product-information_da.pdf)

Deutsch (DE) (1.91 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/de/documents/product-information/unituxin-epar-product-information_de.pdf)

eesti keel (ET) (773.05 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/et/documents/product-information/unituxin-epar-product-information_et.pdf)

ελληνικά (EL) (1.62 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/el/documents/product-information/unituxin-epar-product-information_el.pdf)

français (FR) (781.77 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/fr/documents/product-information/unituxin-epar-product-information_fr.pdf)

hrvatski (HR) (865.09 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/hr/documents/product-information/unituxin-epar-product-information_hr.pdf)

íslenska (IS) (796.42 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/is/documents/product-information/unituxin-epar-product-information_is.pdf)

italiano (IT) (768.83 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/it/documents/product-information/unituxin-epar-product-information_it.pdf)

latviešu valoda (LV) (1.33 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/lv/documents/product-information/unituxin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (866.09 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/lt/documents/product-information/unituxin-epar-product-information_lt.pdf)

magyar (HU) (1.26 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/hu/documents/product-information/unituxin-epar-product-information_hu.pdf)

Malti (MT) (1.33 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/mt/documents/product-information/unituxin-epar-product-information_mt.pdf)

Nederlands (NL) (761.71 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/nl/documents/product-information/unituxin-epar-product-information_nl.pdf)

norsk (NO) (747.42 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/no/documents/product-information/unituxin-epar-product-information_no.pdf)

polski (PL) (1.29 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/pl/documents/product-information/unituxin-epar-product-information_pl.pdf)

português (PT) (744.76 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/pt/documents/product-information/unituxin-epar-product-information_pt.pdf)

română (RO) (886.26 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/ro/documents/product-information/unituxin-epar-product-information_ro.pdf)

slovenčina (SK) (1.27 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sk/documents/product-information/unituxin-epar-product-information_sk.pdf)

slovenščina (SL) (1.26 MB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sl/documents/product-information/unituxin-epar-product-information_sl.pdf)

Suomi (FI) (760.62 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/fi/documents/product-information/unituxin-epar-product-information_fi.pdf)

svenska (SV) (756.97 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sv/documents/product-information/unituxin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/10420/201608 20/03/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Unituxin : EPAR - All Authorised presentations

English (EN) (454.19 KB - PDF)

**First published:** 01/09/2015

**Last updated:** 28/04/2017

[View](/en/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-771)

български (BG) (515.95 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/bg/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_bg.pdf)

español (ES) (457.14 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/es/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (505.78 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/cs/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (457.1 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/da/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (919.01 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/de/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (453.87 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/et/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (513.19 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/el/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_el.pdf)

français (FR) (454.77 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/fr/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (456.85 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/is/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_is.pdf)

italiano (IT) (456.83 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/it/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (514.29 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/lv/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (492.43 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/lt/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (485.74 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/hu/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (510.69 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/mt/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (457.11 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/nl/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (456.4 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/no/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_no.pdf)

polski (PL) (508.72 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/pl/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_pl.pdf)

português (PT) (454.32 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/pt/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_pt.pdf)

română (RO) (496.73 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/ro/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (957.17 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sk/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.34 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sl/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (453.8 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/fi/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (457.32 KB - PDF)

**First published:**

01/09/2015

**Last updated:**

28/04/2017

[View](/sv/documents/all-authorised-presentations/unituxin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Unituxin Active substance Dinutuximab International non-proprietary name (INN) or common name dinutuximab Therapeutic area (MeSH) Neuroblastoma Anatomical therapeutic chemical (ATC) code L01FX06

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). It is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin.

## Authorisation details

EMA product number EMEA/H/C/002800 Marketing authorisation holder

United Therapeutics Europe Ltd

Uniter House

Opinion adopted 21/05/2015 Marketing authorisation issued 14/08/2015 Withdrawal of marketing authorisation 20/03/2017 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Unituxin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (527.07 KB - PDF)

**First published:** 04/08/2016

**Last updated:** 28/04/2017

[View](/en/documents/procedural-steps-after/unituxin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Unituxin : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/408316/2015

English (EN) (6.29 MB - PDF)

**First published:** 01/09/2015

**Last updated:** 28/04/2017

[View](/en/documents/assessment-report/unituxin-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Unituxin

Adopted

Reference Number: EMA/CHMP/303761/2015

English (EN) (504.09 KB - PDF)

**First published:** 22/05/2015

**Last updated:** 28/04/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-unituxin_en.pdf)

#### News on Unituxin

[EMA recommends treatment for rare cancer in children](/en/news/ema-recommends-treatment-rare-cancer-children) 22/05/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2015) 22/05/2015

#### More information on Unituxin

This product was originally designated an [orphan medicine](/en/medicines/human/orphan-designations/eu-3-11-879) on 21 June 2011. Unituxin was withdrawn from the Community register of orphan medicinal products by the European Commission in March 2017 at the time of the withdrawal of the marketing authorisation.

#### More information on Unituxin

- [EMEA-001285-PIP01-12-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001285-pip01-12-m02)

**This page was last updated on** 28/04/2017

## Share this page

[Back to top](#main-content)